Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle
Abstract The goal of the study was to evaluate the effect of adding linagliptin to metformin and lifestyle on glucose levels and pancreatic β-cell function in patients with persistent impaired glucose tolerance (IGT) after 12 months of metformin and lifestyle. A single center parallel double-blind r...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8a85352854e042bdac3e622b33f7667c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8a85352854e042bdac3e622b33f7667c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8a85352854e042bdac3e622b33f7667c2021-12-02T18:27:49ZEffect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle10.1038/s41598-021-88108-82045-2322https://doaj.org/article/8a85352854e042bdac3e622b33f7667c2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88108-8https://doaj.org/toc/2045-2322Abstract The goal of the study was to evaluate the effect of adding linagliptin to metformin and lifestyle on glucose levels and pancreatic β-cell function in patients with persistent impaired glucose tolerance (IGT) after 12 months of metformin and lifestyle. A single center parallel double-blind randomized clinical trial with 6 months of follow-up was performed in patients with persistent IGT after 12 months of treatment with metformin and lifestyle; patients were randomized to continue with metformin 850 mg twice daily (M group, n = 12) or linagliptin/metformin 2.5/850 mg twice daily (LM group, n = 19). Anthropometric measurements were obtained by standard methods and by bioelectrical impedance; glucose was measured by dry chemistry, insulin by chemiluminescence, and pancreatic β-cell function was calculated with the disposition index using glucose and insulin values during oral glucose tolerance test (OGTT) and adjusting by insulin sensitivity. The main outcomes were glucose levels during OGTT and pancreatic β-cell function. Patients in the LM group had a reduction in weight (−1.7 ± 0.6, p < 0.05) and body mass index (BMI, −0.67 ± 0.2, p < 0.05). Glucose levels significantly improved in LM group with a greater reduction in the area under the glucose curve during OGTT (AUCGluc0_120min) as compared to the M group (−4425 ± 871 vs −1116 ± 1104 mg/dl/120 min, p < 0.001). Pancreatic β-cell function measured with the disposition index, improved only in LM group (2.3 ± 0.23 vs 1.7 ± 0.27, p 0.001); these improvements persisted after controlling for OGTT glucose levels. The differences in pancreatic β-cell function persisted also after pairing groups for basal AUCGluc0_120min. The addition of linagliptin to patients with persistent IGT after 12 months of treatment with metformin and lifestyle, improved glucose levels during OGTT and pancreatic β-cell function after 6 months of treatment. Trial registration: Clinicaltrials.gov with the ID number NCT04088461Mildred Fátima de la Luz Alvarez-CanalesSara Stephania Salazar-LópezDiana Farfán-VázquezYosceline Estrella Martínez-LópezJessica Noemí González-MenaLilia Marisela Jiménez-CejaKatya Vargas-OrtizMaría Lola Evia-ViscarraMaría Luisa Montes de Oca-LoyolaFranco FolliAlberto Aguilar-GarcíaRodolfo Guardado-MendozaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Mildred Fátima de la Luz Alvarez-Canales Sara Stephania Salazar-López Diana Farfán-Vázquez Yosceline Estrella Martínez-López Jessica Noemí González-Mena Lilia Marisela Jiménez-Ceja Katya Vargas-Ortiz María Lola Evia-Viscarra María Luisa Montes de Oca-Loyola Franco Folli Alberto Aguilar-García Rodolfo Guardado-Mendoza Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle |
| description |
Abstract The goal of the study was to evaluate the effect of adding linagliptin to metformin and lifestyle on glucose levels and pancreatic β-cell function in patients with persistent impaired glucose tolerance (IGT) after 12 months of metformin and lifestyle. A single center parallel double-blind randomized clinical trial with 6 months of follow-up was performed in patients with persistent IGT after 12 months of treatment with metformin and lifestyle; patients were randomized to continue with metformin 850 mg twice daily (M group, n = 12) or linagliptin/metformin 2.5/850 mg twice daily (LM group, n = 19). Anthropometric measurements were obtained by standard methods and by bioelectrical impedance; glucose was measured by dry chemistry, insulin by chemiluminescence, and pancreatic β-cell function was calculated with the disposition index using glucose and insulin values during oral glucose tolerance test (OGTT) and adjusting by insulin sensitivity. The main outcomes were glucose levels during OGTT and pancreatic β-cell function. Patients in the LM group had a reduction in weight (−1.7 ± 0.6, p < 0.05) and body mass index (BMI, −0.67 ± 0.2, p < 0.05). Glucose levels significantly improved in LM group with a greater reduction in the area under the glucose curve during OGTT (AUCGluc0_120min) as compared to the M group (−4425 ± 871 vs −1116 ± 1104 mg/dl/120 min, p < 0.001). Pancreatic β-cell function measured with the disposition index, improved only in LM group (2.3 ± 0.23 vs 1.7 ± 0.27, p 0.001); these improvements persisted after controlling for OGTT glucose levels. The differences in pancreatic β-cell function persisted also after pairing groups for basal AUCGluc0_120min. The addition of linagliptin to patients with persistent IGT after 12 months of treatment with metformin and lifestyle, improved glucose levels during OGTT and pancreatic β-cell function after 6 months of treatment. Trial registration: Clinicaltrials.gov with the ID number NCT04088461 |
| format |
article |
| author |
Mildred Fátima de la Luz Alvarez-Canales Sara Stephania Salazar-López Diana Farfán-Vázquez Yosceline Estrella Martínez-López Jessica Noemí González-Mena Lilia Marisela Jiménez-Ceja Katya Vargas-Ortiz María Lola Evia-Viscarra María Luisa Montes de Oca-Loyola Franco Folli Alberto Aguilar-García Rodolfo Guardado-Mendoza |
| author_facet |
Mildred Fátima de la Luz Alvarez-Canales Sara Stephania Salazar-López Diana Farfán-Vázquez Yosceline Estrella Martínez-López Jessica Noemí González-Mena Lilia Marisela Jiménez-Ceja Katya Vargas-Ortiz María Lola Evia-Viscarra María Luisa Montes de Oca-Loyola Franco Folli Alberto Aguilar-García Rodolfo Guardado-Mendoza |
| author_sort |
Mildred Fátima de la Luz Alvarez-Canales |
| title |
Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle |
| title_short |
Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle |
| title_full |
Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle |
| title_fullStr |
Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle |
| title_full_unstemmed |
Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle |
| title_sort |
effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/8a85352854e042bdac3e622b33f7667c |
| work_keys_str_mv |
AT mildredfatimadelaluzalvarezcanales effectoflinagliptinonglucosemetabolismandpancreaticbetacellfunctioninpatientswithpersistentprediabetesaftermetforminandlifestyle AT sarastephaniasalazarlopez effectoflinagliptinonglucosemetabolismandpancreaticbetacellfunctioninpatientswithpersistentprediabetesaftermetforminandlifestyle AT dianafarfanvazquez effectoflinagliptinonglucosemetabolismandpancreaticbetacellfunctioninpatientswithpersistentprediabetesaftermetforminandlifestyle AT yoscelineestrellamartinezlopez effectoflinagliptinonglucosemetabolismandpancreaticbetacellfunctioninpatientswithpersistentprediabetesaftermetforminandlifestyle AT jessicanoemigonzalezmena effectoflinagliptinonglucosemetabolismandpancreaticbetacellfunctioninpatientswithpersistentprediabetesaftermetforminandlifestyle AT liliamariselajimenezceja effectoflinagliptinonglucosemetabolismandpancreaticbetacellfunctioninpatientswithpersistentprediabetesaftermetforminandlifestyle AT katyavargasortiz effectoflinagliptinonglucosemetabolismandpancreaticbetacellfunctioninpatientswithpersistentprediabetesaftermetforminandlifestyle AT marialolaeviaviscarra effectoflinagliptinonglucosemetabolismandpancreaticbetacellfunctioninpatientswithpersistentprediabetesaftermetforminandlifestyle AT marialuisamontesdeocaloyola effectoflinagliptinonglucosemetabolismandpancreaticbetacellfunctioninpatientswithpersistentprediabetesaftermetforminandlifestyle AT francofolli effectoflinagliptinonglucosemetabolismandpancreaticbetacellfunctioninpatientswithpersistentprediabetesaftermetforminandlifestyle AT albertoaguilargarcia effectoflinagliptinonglucosemetabolismandpancreaticbetacellfunctioninpatientswithpersistentprediabetesaftermetforminandlifestyle AT rodolfoguardadomendoza effectoflinagliptinonglucosemetabolismandpancreaticbetacellfunctioninpatientswithpersistentprediabetesaftermetforminandlifestyle |
| _version_ |
1718377991242776576 |